Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy

BACKGROUND: Inhibition of activin/myostatin pathway has emerged as a novel approach to increase muscle mass and bone strength. Duchenne muscular dystrophy (DMD) is a neuromuscular disorder that leads to progressive muscle degeneration and also high incidence of fractures. The aim of our study was to...

Full description

Saved in:
Bibliographic Details
Published in:BMC Musculoskelet Disord
Main Authors: Puolakkainen, Tero, Ma, Hongqian, Kainulainen, Heikki, Pasternack, Arja, Rantalainen, Timo, Ritvos, Olli, Heikinheimo, Kristiina, Hulmi, Juha J., Kiviranta, Riku
Format: Artigo
Language:Inglês
Published: BioMed Central 2017
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5244551/
https://ncbi.nlm.nih.gov/pubmed/28103859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12891-016-1366-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items